PARP1 and cancer: Thus, the USP7 inhibitors can offer the chance to modulate the growth ability of prostate cancer cells: on one side they can, by downregulating the levels of both isoforms, negatively modulate the AR-FL and the ARV7 dependent proliferative and trascriptional abilities; on the other side by downregulating CCDC6, they can affect the homologous directed DNA repair and sensitize the castration resistant cancer cells to the PARP inhibitors treatment.